The expression of versican and its role in pancreatic neuroendocrine tumors
- 1 January 2020
- journal article
- research article
- Published by Elsevier in Pancreatology
- Vol. 20 (1) , 142-147
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81472785, 61435001)
- CAMS Innovation Fund for Medical Sciences (2017-I2M-1-001, 2016-I2M-1-001)
This publication has 21 references indexed in Scilit:
- The New World Health Organization Classification for Pancreatic Neuroendocrine NeoplasiaEndocrinology and Metabolism Clinics of North America, 2018
- DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumorsOncotarget, 2017
- Loss of DAXX and ATRX Are Associated With Chromosome Instability and Reduced Survival of Patients With Pancreatic Neuroendocrine TumorsGastroenterology, 2014
- KRAS and DAXX/ATRX Gene Mutations Are Correlated with the Clinicopathological Features, Advanced Diseases, and Poor Prognosis in Chinese Patients with Pancreatic Neuroendocrine TumorsInternational Journal of Biological Sciences, 2014
- Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain–associated protein in neuroendocrine tumorsHuman Pathology, 2013
- DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine TumorsScience, 2011
- MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of casesEndocrine-Related Cancer, 2010
- 3. The ENETS Guidelines: The New TNM Classification SystemTumori Journal, 2010
- Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR PathwayJournal of Clinical Oncology, 2010
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008